BACKGROUND: The aim of this study was to analyze the prognostic implications of pretreatment circulating endothelial cells (CECs) and circulating endothelial progenitor cells (CEPCs) for the survival of @entity1 with @entity2 . MATERIALS AND METHODS: Relevant literature was identified using Medline and EMBASE. @entity1 clinical characteristics, @entity1349 ( @entity1349 ) and progression-free survival (PFS) together with CEC and CEPC positive rates before treatment were extracted. STATA 12.0 was used for our analysis and assessment of publication bias. RESULTS: A total of 13 articles (8 for CEC and 5 for CEPC, n=595 and n=244) were pooled for the global meta-analysis. The odds ratio (OR) for @entity1349 predicted by pretreatment CECs was 1.641 [0.967, 2.786], while the OR for PFS was 1.168 [0.649, 2.100]. The OR for @entity1349 predicted by pretreatment CEPCs was 12.673 [5.274, 30.450], while the OR for PFS was 4.930 [0.931, 26.096]. Subgroup analyses were conducted according to clinical staging. Odds ratio (OR) showed the high level of pretreatment CECs only correlated with the @entity1349 of @entity1 with advanced @entity2 (stage III-IV). CONCLUSIONS: High counts of CECs seem to be associated only with worse 1-year @entity1349 in @entity1 with @entity2 , while high level of pretreatment CEPCs correlate with both worse PFS and @entity1349 .

Meta-Analysis of Circulating Endothelial Cells and Circulating Endothelial Progenitor Cells as Prognostic Factors in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patient'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity2 :: (MESH:D008175,Disease) :: ['Lung Cancer']
